Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STORM’s METTL3 Inhibitor Effective Against AML

Plans Global Clinical RNA Epigenetic Drug Program in early 2022

Executive Summary

Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.

You may also be interested in...



Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

Exelixis Moves Into RNA-Modifying Cancer Therapy With Storm Pact

Deal Snapshot: In addition to investigating the ADAR1 target with the UK biotech, Exelixis also has optioned a second candidate for non-Hodgkin’s lymphoma under its 2019 deal with Aurigene.

Teva, CRT Build On Tie That Produced aPKC Protein Inhibitor Candidate

By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel